Compass raises $80M to take [synthetic psilocybin] drug toward phase 3
The London-based biotech is advancing the drug, [one of the many] active ingredient[s] in magic mushrooms … Compass has partnered with academic centers, primarily in the U.S. …is advancing the clinical program while also working on earlier-stage projects. The biotech… focuse[s] on psilocybin therapy in the belief it could leverage existing knowledge of the drug…
Recent Comments